LIFR and cancer: Editing at the fifth position of the mature miR-200b-3p impairs the ability to inhibit ZEB1/ZEB2 and acquires a new target-leukemia inhibitory factor receptor (LIFR)-conferring a net effect of increasing motility and invasion in a series of cancer cell lines [34].